Subscribe To
RZLT / Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Read More
Posted: Mar 24 2022, 15:03
Author Name: Zacks Investment Research
Views: 103126
RZLT News
By Zacks Investment Research
March 24, 2022
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperin more_horizontal